Cancer and Heart Disease

Dr. Tochi M. Okwuosa

Director, Cardio-Oncology Program at Rush University Medical Center

Residual Risk Seen From Elevated Lipoprotein A But Not Apolipoprotein B or Non-HDL Cholesterol in Patients at Heart Centers for Women

Briana Costello, Nicole Pohlman, Kyla Lara, Gina Lundberg, Rami Doukky, Lynne Braun, Annabelle Volgman

Purpose: To determine the residual risk after accounting for traditional risk markers in women seen in heart centers for women (HCW). Elevated lipoprotein a (Lpa) may be an important indicator of increased risk of cardiovascular (CV) events and should be tested for in all patients.

Methods:  Patients from Chicago and Atlanta HCW received a blood test that was sent to the Berkeley Heart Lab. The results measured traditional and non-traditional markers of risk, such as Lpa and apolipoprotein B (apoB). The residual risk was then analyzed by identifying discordance between low-density lipoprotein cholesterol (LDL) and non-high-density lipoprotein cholesterol (NHDL), apoB, and Lpa.

Conclusions: LDL vs. NHDL and apoB had minimal discordance with good correlation, while LDL and Lpa showed significant discordance with weak correlation. This calls for new drugs that lower both LDL and Lpa levels in order to reduce CV risk in these women.

Do the New Atherosclerotic Cardiovascular Disease Guidelines Agree with Reynold’s Risk Score for Women? 

Briana T Costello, Eric R Silverman, Nicole Pohlman, Benjamin Gastevich, Josephine Kooijman, Noreen Nazir, Rasa Kazlauskaite, Gina Lundberg, Rami Doukky, Bala Hota, Lynne T Braun, Kim A Williams, Annabelle S Volgman

Click here or below to view the poster presented at the 2015 American College of Cardiology Scientific Session

Is There Any Correlation Between CHA2DS2-VASC Score to Left Atrial Volume Index?

Hena Patel MD, Noreen Nazir MD, Annabelle Volgman MD

Click here or below to view the poster presented at the 32nd annual Rush University Forum for Research and Clinical Investigation